专题论文

阿尔茨海默病伴发视觉障碍研究进展

  • 金朝 ,
  • 张巍
展开
  • 1. 首都医科大学附属北京天坛医院神经病学中心, 北京 100050;
    2. 首都医科大学附属北京天坛医院国家神经系统疾病临床医学研究中心, 北京 100050;
    3. 首都医科大学教育部神经变性疾病重点实验室, 北京 100069;
    4. 北京脑重大疾病研究院, 北京 100069
金朝,硕士研究生,研究方向为阿尔茨海默病的临床特征、神经病理、发病机制及神经影像学,电子信箱:352487538@qq.com

收稿日期: 2016-12-02

  修回日期: 2017-02-04

  网络出版日期: 2017-02-28

基金资助

国家重点研发计划重点专项(2016YFC1306000,2016YFC1306300);国家自然科学基金项目(81571229,81071015,30770745,81030062);北京市自然科学基金项目(kz201610025030,4161004,kz200910025001,7082032);国家重点基础研究发展计划(2011CB504100);国家科技重大专项项目(2011ZX09102-003-01);国家科技支撑计划项目(2013BAI09B03);北京脑重大疾病研究院项目(BIBD-PXM2013_014226_07_000084);北京市卫生系统高层次卫生技术人才培养计划项目(2009-3-26);北京市属高等学校创新团队建设与教师职业发展计划项目(IDHT20140514);首都临床特色应用研究(Z12110700100000,Z121107001012161);北京市保健科研课题(京15-2,京15-3);北京市优秀人才培养项目(20071D0300400076);首都医科大学基础-临床科研合作基金项目(2015-JL-PT-X04,14JL5,10JL49);首都医科大学附属北京天坛医院青年科研基金项目(2014-YQN-YS-18,2015-YQN-15,2015-YQN-05,2015-YQN-14,2015-YQN-17)

Research progress of Alzheimer's disease with visual impairment

  • JIN Zhao ,
  • ZHANG Wei
Expand
  • 1. Center of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China;
    2. China National Clinical Research Center for Neurological Disease, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China;
    3. Key Laboratory for Neurodegenerative Disorders, Ministry of Education, Capital Medical University, Beijing 100069, China;
    4. Beijing Institute for Brain Disorders, Beijing 100069, China

Received date: 2016-12-02

  Revised date: 2017-02-04

  Online published: 2017-02-28

摘要

阿尔茨海默病(AD)是老年人群常见的神经变性疾病,多以记忆力损害为首发症状,逐渐出现进行性认知功能受损和精神行为症状,对家庭和社会带来沉重的经济和照护负担。AD早期症状不明显,待诊断明确后的治疗效果差,因此,早期诊断尤为重要。研究发现,AD患者可出现视觉障碍,但尚无流行病学数据。目前AD的治疗包括非药物及药物等综合手段,AD伴发视觉障碍的治疗尚需研究。本文主要介绍AD视觉障碍的临床症状、发生机制、检测及评价手段,包括光学相干体层扫描、视觉诱发电位、视网膜微血管检查及神经影像学,以对AD患者的视觉障碍进行全面评价,寻找特异、敏感及简便的AD评估手段,为AD的早期诊断及早期干预提供依据。

本文引用格式

金朝 , 张巍 . 阿尔茨海默病伴发视觉障碍研究进展[J]. 科技导报, 2017 , 35(4) : 49 -53 . DOI: 10.3981/j.issn.1000-7857.2017.04.008

Abstract

The Alzheimer's disease (AD) is a common neurodegenerative disease among the elderly population with the memory impairment as the initial symptom, gradually followed by the progressive cognitive impairment and the behavioral and psychological symptoms, with heavy economic and care burdens to both family and society. The early symptoms of the AD are not obvious, which causes the poor therapeutic effect after diagnosis, thus early diagnosis is particularly important. Increasing investigations identified the visual impairment in the AD patients, but with no epidemiological data of the AD accompanied with the visual impairment. This paper mainly focuses on the clinical symptoms, the mechanism, the detection and the evaluation approaches of the visual impairment, including the optical coherence tomography, the visual evoked potential, the retinal microvascular examination and the neuroimaging so as to systemically assess the visual impairment, explore the specific, sensitive and simple methods of evaluation of the AD and provide evidence for early diagnosis and intervention of the AD. Comprehensive management of the AD includes non-drug intervention and drug therapy, however, the treatment of the visual impairment in the AD is an important issue.

参考文献

[1] Prince M, Wimo A, Guerchet M, et al. World Alzheimer Report 2015. The global impact of dementia. An analysis of prevalence, incidence, cost and trends[M]. London:Alzheimer's Disease International (ADI), 2015.
[2] Trick G L, Trick L R, Morris P, et al. Visual field loss in senile demen-tia of the Alzheimer's type[J]. Neurology, 1995, 45(1):68-74.
[3] Cordeiro M F, Guo L, Coxon K M, et al. Imaging multiple phases of neurodegeneration:A novel approach to assessing cell death in vivo[J]. Cell Death & Disease, 2010, 1(1):e3.
[4] Tzekov R, Mullan M. Vision function abnormalities in Alzheimer disease[J]. Survey of Ophthalmology, 2014, 59(4):414-433.
[5] Uhlmann R F, Larson E B, Koepsell T D, et al. Visual impairment and cognitive dysfunction in Alzheimer's disease[J]. Journal of General In-ternal Medicine, 1991, 6(2):126-32.
[6] Jefferis J M, Mosimann U P, Clarke M P. Cataract and cognitive impair-ment:A review of the literature[J]. British Journal of Ophthalmology, 2011, 95(1):17-23.
[7] Kirby E, Bandelow S, Hogervorst E. Visual impairment in Alzheimer's disease:A critical review[J]. Journal of Alzheimer's Disease, 2010, 21(1):15-34.
[8] Salamone G, Lorenzo C D, Mosti S et al. Color discrimination perfor-mance in patients with Alzheimer's disease[J]. Dementia & Geriatric Cognitive Disorders, 2009, 27(6):501-507.
[9] Hendry S H, Hsiao S S. Fundamentals of sensory systems[M]//Funda-mental Neuroscience:Fourth Edition. Elsevier Inc., 2012.
[10] Valenti D A. Alzheimer's disease:Screening biomarkers using frequen-cy doubling technology visual field[J]. Isrn Neurology, 2013:989583-989583.
[11] Giovagnoli A R, Erbetta A. Visual contrast sensitivity in AD, MCI, & older adults with cognitive complaints[J]. Neuropsychologia., 2008, 46(5):1495-1504.
[12] Risacher S L, Wudunn D, Pepin S M, et al. Visual contrast sensitivity in Alzheimer's disease, mild cognitive impairment, and older adults with cognitive complaints[J]. Neurobiology of Aging, 2013, 34(4):1133-1144.
[13] Guo L, Duggan J, Cordeiro M F. Alzheimer's disease and retinal neuro-degeneration[J]. Current Alzheimer Research, 2010, 7(1):3-14.
[14] Poling A, Paisleymorgan K, Panos J J, et al. Oligomers of the amyloidbeta protein disrupt working memory:Confirmation with two behavior-al procedures[J]. Behavioural Brain Research, 2004, 69(193):230-234.
[15] Lee Y J, Han S B, Nam S Y, et al. Inflammation and Alzheimer's dis-ease[J]. Archives of Pharmacal Research, 2000, 21(3):383-421.
[16] Thomson K L, Jing M Y, Waddell B, et al. A systematic review and meta-analysis of retinal nerve fiber layer change in dementia, using optical coherence tomography[J]. Alzheimers & Dementia Diagnosis Assessment & Disease Monitoring, 2015, 1(2):136-143.
[17] Ikram M K, Cheung C Y, Wong T Y et al. Retinal pathology as bio-marker for cognitive impairment and Alzheimer's disease[J]. Journal of Neurology Neurosurgery & Psychiatry, 2012, 83(9):917-922.
[18] Blanks J C, Schmidt S Y, Torigoe Y, et al. Retinal pathology in Al-zheimer's diseaseII. Regional neuron loss and glial changes in GCL[J]. Neurobiology of Aging, 1996, 17(3):385-395.
[19] Cheung C Y, Ong Y T, Hilal S et al. Retinal ganglion cell analysis us-ing high-definition optical coherence tomography in patients with mild cognitive impairment and Alzheimer's disease[J]. Journal of Alzheimer's Disease, 2014, 45(1):45-56.
[20] Stothart G, Kazanina N, Tales A, et al. Early visual evoked potentials and mismatch negativity in Alzheimer's disease and mild cognitive impairment:cross-sectional findings and longitudinal follow-up[J]. Journal of Alzheimer's Disease, 2014, 44(2):397-408.
[21] Guo L, Duggan J, Cordeiro M F. Alzheimer's disease and retinal neuro-degeneration[J]. Current Alzheimer Research, 2010, 7(1):3-14.
[22] Cheung C Y, Ong Y T, Ikram M K, et al. Retinal microvasculature in Alzheimer's disease[J]. Journal of Alzheimer's Disease, 2014, 42(s4):S339-S352.
[23] Frost S, Kanagasingam Y, Sohrabi H, et al. Retinal vascular biomark-ers for early detection and monitoring of Alzheimer's disease[J]. Trans-lational psychiatry, 2013, 3(2):e233.
[24] Berisha F, Feke G T, Trempe C L, et al. Retinal abnormalities in early Alzheimer's disease[J]. Investigative Ophthalmology & Visual Sci-ence, 2007, 48(5):2285-2289.
[25] Bozzali M, Falini A, Franceschi M, et al. White matter damage in Alzheimer's disease assessed in vivo using diffusion tensor magnetic resonance imaging[J]. Journal of Neurology, Neurosurgery & Psychia-try, 2002, 72(6):742-746.
[26] Fellgiebel A, Schermuly I, Gerhard A, et al. Functional relevant loss of long association fibre tracts integrity in early Alzheimer's disease[J]. Neuropsychologia, 2008, 46(6):1698-1706.
[27] Stricker N H, Schweinsburg B C, Delano-Wood L, et al. Decreased white matter integrity in late-myelinating fiber pathways in Alzheim-er's disease supports retrogenesis[J]. Neuroimage, 2009, 45(1):10-16.
文章导航

/